Merck (MRK) Stock Slides 3.61% on Thursday, Down 9.6% in Five Sessions
Technical analysis of MRK stock on November 19, 2026: price 132.81 USD, trend downtrend, RSI 31.7, support 132.81, resistance 150.36.

Why MRK is in focus today
- One-day move of 0.00%, about 0.0× its average daily range (ATR)
Selected automatically from 11 NYSE (US) stocks by a technical-signal score with daily weighted randomisation — not a recommendation.
Trend & Price Action
The structural picture is unambiguous. Merck trades below both its 20-day average of $144.93 and its 50-day average of $145.48, and those two averages have just crossed: a death cross formed one session before the latest close, with the 20-day average slicing beneath the 50-day. That configuration is the textbook marker of a short-term trend turning against a longer one, and it is not a one-off blip — the 20-day average itself fell 0.98% over the past five sessions, confirming a downtrend rather than a flat consolidation.
Oscillators & Momentum
Momentum readings confirm the trend rather than fighting it. The RSI(14) at 31.7 is technically "neutral" by the label but is hugging the oversold threshold of 30 — close enough that a reflex bounce is possible, though not evidence of a reversal. The Stochastic oscillator is more emphatic: %K at 6.6 and %D at 7.4, deeply oversold territory where selling pressure has been relentless.
Volatility & Volume
Volatility is mid-range, which sharpens the message. ATR(14) stands at $4.36, or 3.3% of the price — moderate, not a panic regime — and Bollinger band width is 11.7%, described as normal. Yet the latest close has pushed %B to -22%, meaning price has closed below the lower band at $136.47. In plain terms: the squeeze has resolved downward, and the stock is trading outside its normal statistical envelope. Volume backs the move. The last session saw 13,593,500 shares change hands, about 1.5× the 20-day average of 9,187,375, and On-Balance Volume is falling. Heavy volume on a decline with deteriorating OBV is participation confirming the direction — distribution, not accumulation. One note on the selection signal: the day's move measured 0.00% against roughly 0.0× the average daily range, a flat daily range after the prior slide, which in context reads as a pause inside a downtrend rather than a base.Fundamental Context
The filings offer a counterweight worth stating plainly. According to its SEC filing, Merck reported quarterly revenue of $18.09 billion for the quarter ended September 30, 2026, up 4.7% from $17.28 billion a year earlier. Net income was $5.07 billion versus $5.79 billion a year prior, with diluted earnings per share of $2.04. Revenue is growing while profit is compressing — a mix the market has clearly priced as a negative, given the price action. Merck also filed a Form 8-K on November 18, 2026, reporting a change of directors or officers, a governance event that lands in the middle of a technical breakdown.Key Levels & Scenarios
The lines to watch are tight. Resistance sits at $150.36, the 20-day high; support is the $132.81 shelf now acting as the last line before the $131.36 three-month low. If price breaks decisively below $131.36, the path of least resistance opens lower with no nearby technical floor from the data. If the $132.81 shelf holds and buyers absorb the oversold stochastic, the first meaningful test is the lower Bollinger band at $136.47 — reclaiming it would be the earliest sign the downside momentum is stalling. Until then, every bounce is a countertrend move.Technical Verdict: SELL
The verdict is SELL, backed by a computed score of -84 on a −100 to +100 scale (the model flags a sell at −60 or below), with three bearish drivers against zero bullish: the fresh death cross, the Bollinger squeeze resolved with a close below the lower band, and a downtrend confirmed by falling OBV. Price below the 50-day average and a 20-day average beneath the 50-day seal the case. - Sell zone: $132.81 – $136.08 - Exit target 1: $121.67 | Exit target 2: $110.52 - Stop loss: $140.24 (above the lower band, protecting against a squeeze reversal) - Reward/risk: 1.5 / 3.0 | Valid until December 18, 2026 The call is invalidated if price breaks above the stop at $140.24, which would signal the oversold stochastic at 6.6 has produced a genuine reversal rather than a pause. In plain English: Merck is trending down on heavy volume with no confirmed bottom, and the charts favor staying defensive until the $132.81 floor either breaks or decisively holds. The next scheduled catalyst is the December 18, 2026 validity date on the current setup — the deadline by which the sell thesis either plays out toward $121.67 or expires. This is technical analysis based on exchange data and company filings, not an investment recommendation.Summary Data MRK
| Last price | 132.81 USD |
| Change 1 day / 5 days / 1 month | -3.61% / -9.62% / -9.80% |
| Trend / MA-cross | downtrend / death |
| SMA20 / SMA50 | 144.93 / 145.48 |
| RSI (14) / Stochastic %K | 31.7 / 6.6 |
| Bollinger %B / ATR | -22% / 4.36 |
| Support / Resistance 20 days | 132.81 / 150.36 |
| Data as of | 20 November 2026 04:03 WIB |
| JournalArta research verdict (score) | Sell (-84) |
| Sell zone | 132.81 – 136.08 |
| Target 1 / 2 | 121.67 / 110.52 |
| Stop loss | 140.24 |
| Reward/risk | 1.5 / 3.0 |
Today's full Buy and Sell list for US stocks →
Disclaimer: This technical analysis is generated automatically from exchange data and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.
Track MRK stock price daily: live levels, support/resistance and our full MRK analysis history.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Lifestyle · Food & HealthNormal Blood Pressure Chart by Age: Healthy Ranges Explained
Lifestyle · Food & HealthWhat Is Raynaud’s Syndrome? Why Fingers Turn White in the Cold
Lifestyle · Food & Health4 Ways Walking After Meals Helps Your Body, Doctors Say
Lifestyle · Food & Health4 Reasons to Eat Oatmeal, According to Nutrition Experts


















